Navigation Links
Galenea Awarded RC1 Challenge Grant to Develop Predictive In Vivo Models of Cognition
Date:10/6/2009

CAMBRIDGE, Mass., Oct. 6 /PRNewswire/ -- Galenea Corp., a fully-integrated CNS drug discovery company, announced today that it has been awarded an NIH Challenge Grant in Health and Science Research (RC1) as part of the American Recovery and Reinvestment Act of 2009 (Recovery Act). This two-year grant from the National Institute of Mental Health addresses the specific topic of "Screening Approaches to Identify Pharmacologic Treatments for Mental Disorders" within the challenge area of Translational Science. The grant provides approximately $1 million to support the development of an innovative model for predicting the activity of potential treatments for impaired cognition in diseases such as schizophrenia. The program is part of Galenea's ongoing effort to pioneer new practices for objective measures in CNS drug discovery.

Schizophrenia is a devastating mental illness affecting about 1% of the global population. Currently available treatments can ameliorate some of the symptoms including the hallmark delusions and hallucinations but are not effective at treating the social isolation or the cognitive defects that afflict people with the disease. Traditional methods for assessing changes in cognition, such as impairments in attention and working memory, are very limited. This makes the development of new treatments for cognitive impairment very challenging. Galenea's unique in vivo approach to evaluating potential drug candidates for their pro-cognitive effects could lead to novel therapeutics for schizophrenia and other psychiatric diseases.

"The award serves as an endorsement of our approach to developing revolutionary analytical tools for measuring neuronal function and thereby increases the likelihood that viable drug treatments will reach the market", said David Gerber, Galenea's founder and VP of CNS Research. "This technology is part of our broader proprietary platform for monitoring neuronal network activity. We b
'/>"/>

SOURCE Galenea Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
2. USC neuroscientists awarded $9 million to map gene expression during human brain development
3. $16.8 million grant awarded to develop platelet recovery treatments
4. The Ambrosia Treatment Centers Awarded Gold Seal of Approval by the Joint Commission
5. Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine
6. Loyola University Chicago awarded scholarships for accelerated nursing students
7. Brookhaven Labs Joanna Fowler to be awarded National Medal of Science
8. Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant
9. Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent
10. $450,000 Awarded for Innovative Asthma Research Into Death by Drowning in Mucus
11. BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... (PRWEB) March 04, 2015 When people talk ... the top artists spread across numerous genres, the Houston ... the conversation. Each night during the annual livestock show and ... addition to the other activities being held at the event. ... groups of performers that will try and get the festival ...
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... Falls Church, VA (PRWEB) March 04, 2015 ... in Four Hours , **FDAnews Webinar**, March 24, 2015 ... , FDA investigators generally know within four hours ... not. If the manufacturer is on their “good” list, ... they’re doing. If a manufacturer is on the “bad” ...
(Date:3/4/2015)... The ability of volumetric breast imaging ... help improve breast cancer risk prediction models is ... at the European Congress of Radiology (ECR) meeting, ... posters and 2 session presentations - highlight the ... quantitative breast imaging software tools to provide insight ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 With the growing ... the lives of our teens and young adults, combined with ... difficult and confusing to try to keep up with what ... fad or trend is replaced on a daily basis. , ... substances, and the slang that is used to discreetly talk ...
Breaking Medicine News(10 mins):Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2
... Ind. - A Purdue University research team developed a ... as needed for extending the shelf life of foods ... an assistant professor of food science, altered the surface ... which led to the creation of several forms of ...
... health concerns about increasing antiviral resistance among certain influenza ... alternative antiviral treatment options. The findings are published in ... Infectious Diseases . (Please see below for links to ... two classes of drugs: M2 blockers (adamantanes) and neuraminidase ...
... has contributed to a study showing that a low dose ... study is published in today,s Lancet . , ... Rothwell in Oxford, and is based on an overview of ... with reducing heart attacks, but have also gathered information on ...
... , MONDAY, Dec. 6 (HealthDay News) -- Long-term ... of dying from a wide array of cancers, a new ... that a low-dose aspirin (75 milligrams) taken daily for at ... percent drop in fatalities depending on the type of cancer. ...
... Physical Therapy Association (APTA) is pointing to a new study ... to encourage the newly established Center for Medicare and Medicaid ... to physical therapist services that was recommended in the recent ... Spine , showed Medicare patients who received physical therapy ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- Applying sunscreen ... chances of getting melanoma by half, a new study has found. ... 25 to 75 into two groups. One group was told to ... for five years between 1992 and 1996. The other group was ...
Cached Medicine News:Health News:Nanoparticle gives antimicrobial ability to fight Listeria longer 2Health News:Influenza virus strains show increasing drug resistance and ability to spread 2Health News:Influenza virus strains show increasing drug resistance and ability to spread 3Health News:Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent 2Health News:Daily Aspirin Linked to Steep Drop in Cancer Risk 2Health News:Daily Aspirin Linked to Steep Drop in Cancer Risk 3Health News:Early physical therapy for low back pain associated with less subsequent health care utilization 2Health News:Daily Sunscreen Use Does Protect from Melanoma, Study Finds 2Health News:Daily Sunscreen Use Does Protect from Melanoma, Study Finds 3
(Date:3/4/2015)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... II proof of concept clinical study investigating the ... in the treatment of chronic pruritus in patients ... clinically meaningful improvement from baseline by tradipitant (40.5mm ... 100mm unit Visual Analog Scale (VAS) for itch, ...
(Date:3/4/2015)... China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or ... in China, today announced its financial results for the ... Fourth Quarter 2014 Financial Highlights , Total ... 36.2%, or 36.8% excluding the impact of foreign currency ... in the same quarter of 2013. , Gross ...
(Date:3/4/2015)... GSI Group Inc. (NASDAQ: GSIG ... and supplier of precision photonics and motion control components ... technology markets, today reported financial results for the fourth ... financial results in this press release are GAAP measures ... fourth quarter of 2014, GSI generated revenue of $94.0 ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9
... Aug. 28 Intercell AG (VSE: ICLL) today,announced ... initiated a Phase II,clinical trial of V710, an ... aureus) infections. This randomized double blind,placebo controlled study ... vaccine candidate in patients with end-stage kidney disease ...
... Prevent ... Onset of Parkinson,s Disease, CHICAGO, Aug. 27 The British ... made a crucial breakthrough in the battle to slow or prevent ... The researchers have genetically produced the first ever mouse model,with ...
Cached Medicine Technology:Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 2Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 3The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: